Top

Published in:

01-01-2013 | Original Article

Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012

Authors: Ruri Kikura-Hanajiri, Nahoko Uchiyama, Maiko Kawamura, Yukihiro Goda

Published in: Forensic Toxicology | Issue 1/2013

Abstract

The changes in the prevalence of designer drugs and their legal status in Japan were investigated on the basis of the analyses of 686 different products containing synthetic cannabinoids and/or cathinone derivatives obtained from 2009 to February 2012. In the early stages of distribution of herbal-type products containing synthetic cannabinoids, cyclohexylphenols and naphthoylindoles were mostly found in the products. In November 2009, however, cannabicyclohexanol, CP-47,497 and JWH-018 were controlled as “designated substances” under the Pharmaceutical Affairs Law in Japan, and the cyclohexylphenols have since disappeared from the illegal drug market and been replaced by various analogs of the naphthoylindoles, phenylacetylindoles and benzoylindoles. These compounds, which have high affinities for the cannabinoid CB₁ receptor, have become very popular, and the number of emergency hospitalizations associated with their use has dramatically increased from 2011. Other synthetic compounds with different structures and pharmacological effects, such as cathinone derivatives, have been detected together with the synthetic cannabinoids in herbal-type products since 2011. Moreover, many new types of synthetic cannabinoids, different from the four typical structures described, have also begun to appear since 2011. In addition to the synthetic cannabinoids, liquid or powdery-type products containing cathinone derivatives have been widely distributed recently. In 2009, the most popular cathinone derivative was 4-methylmethcathinone. After this compound was controlled as a designated substance in November 2009, cathinone derivatives, which have a pyrrolidine structure at the nitrogen atom and a 3,4-methylenedioxy structure, or analogs of 4-methylmethcathinone, became popular. In the present analysis, tryptamines were also detected in 31 % of the products containing cathinone derivatives. Local anesthetics such as procaine, lidocaine, benzocaine and dimethocaine were also frequently detected. In total, we identified at least 35 synthetic cannabinoids and 22 cathinone derivatives during this survey.

Kikura-Hanajiri R, Uchiyama N, Kawamura M, Ogata J, Goda Y (2012) Prevalence of new designer drugs and their legal status in Japan (in Japanese with English abstract). Yakugaku Zasshi (in press)

Kikura-Hanajiri R, Uchiyama N, Goda Y (2011) Survey of current trends in the abuse of psychotropic substances and plants in Japan. Legal Med 13:109–115PubMedCrossRef

Nagashima M, Seto T, Takahashi M, Miyake H, Yasuda I (2004) Screening method of the chemical illegal drugs by HPLC-PDA (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 55:67–71

Kikura-Hanajiri R, Hayashi M, Saisho K, Goda Y (2005) Simultaneous determination of 19 hallucinogenic tryptamines/β-calbolines and phenethylamines using GC–MS and LC-ESI–MS. J Chromatogr B 825:29–37CrossRef

Seto T, Takahashi M, Nagashima M, Suzuki J, Yasuda I (2005) The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 56:75–80

Matsumoto T, Kikura-Hanajiri R, Kamakura H, Kawamura N, Goda Y (2006) Identification of N-Methyl-4-(3,4-methylenedioxyphenyl)butan-2-amine, distributed as MBDB. J Health Sci 52:805–810CrossRef

Takahashi M, Suzuki J, Nagashima M, Seto T, Yasuda I (2007) Newly detected compounds in uncontrolled drugs purchased in Tokyo between April 2006 and March 2007 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 58:83–87

Kikura-Hanajiri R, Kawamura M, Saisho K, Kodama Y, Goda Y (2007) The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. J Chromatogr B 855:121–126CrossRef

Kikura-Hanajiri R, Kawamura M, Uchiyama N, Ogata J, Kamakura H, Saisho K, Goda Y (2008) Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part I: GC–MS and LC–MS (in Japanese with English abstract). Yakugaku Zasshi 128:971–979PubMedCrossRef

10.

Uchiyama N, Kawamura M, Kamakura H, Kikura-Hanajiri R, Goda Y (2008) Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part II: color test and TLC (in Japanese with English abstract). Yakugaku Zasshi 128:981–987PubMedCrossRef

11.

Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2008) Analysis of designer drugs detected in the products purchased in fiscal year 2006 (in Japanese with English abstract). Yakugaku Zasshi 128:1499–1505PubMedCrossRef

12.

Suzuki J, Takahashi M, Seto T, Nagashima M, Okumoto C, Yasuda I (2006) Qualitative method of nitrite inhalants (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 57:115–120

13.

Nagashima M, Seto T, Takahashi M, Suzuki J, Mori K, Ogino S (2008) Analyses of uncontrolled drugs purchased from April 2007 to March 2008 and newly found compounds (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 59:71–77

14.

Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y (2010) Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008 (in Japanese with English abstract). Yakugaku Zasshi 130:263–270PubMedCrossRef

15.

Nagashima M, Takahashi M, Suzuki J, Seto T, Mori K, Ogino S (2009) Analyses of uncontrolled drugs purchased Apr. 2008–Mar. 2009 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 60:81–84

16.

Kikura-Hanajiri R, Kawamura M, Miyajima A, Sunouchi M, Goda Y (2010) Determination of a new designer drug, N-hydroxy-3,4-methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography-tandem mass spectrometry. Forensic Sci Int 198:62–69PubMedCrossRef

17.

Suzuki J, Moriyasu T, Nagashima M, Kanai C, Shimizu M, Hamano T, Nagayama T (2010) Analysis of uncontrolled drugs purchased in fiscal year 2009 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 61:163–172

18.

Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRef

19.

Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31–38PubMedCrossRef

20.

Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218–226PubMed

21.

Huffman JW (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. In: Reggio PH (ed) The cannabinoid receptors. Humana Press, New York, pp 49–94CrossRef

22.

Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31–38PubMedCrossRef

23.

Nagashima M, Suzuki J, Moriyasu T, Yoshida M, Shimizu M, Hamano T, Nakae D (2011) Analysis of uncontrolled drugs purchased in the fiscal year 2010 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 62:99–105

24.

Yoshida M, Suzuki J, Takahashi M, Moriyasu T, Nakajima J, Kanai C, Nagashima M, Seto T, Shimizu M, Hamano T, Nakae D (2011) Investigations of designated substances detected from April 2010 to March 2011 (in Japanese). Ann Rep Tokyo Metrop Inst Public Health 62:107–114

25.

Uchiyama N, Kikura-Hanajiri R, Shoda T, Fukuhara K, Goda Y (2011) Isomeric analysis of synthetic cannabinoids detected as designer drugs (in Japanese with English abstract). Yakugaku Zasshi 131:1141–1147PubMedCrossRef

26.

Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2011) Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH-073, as designer drugs in illegal products. Forensic Toxicol 29:25–37CrossRef

27.

Uchiyama N, Kikura-Hanajiri R, Goda Y (2011) Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB₁ and CB₂ receptors. Chem Pharm Bull 59:1203–1205PubMedCrossRef

28.

Nakajima J, Takahashi M, Seto T, Suzuki J (2011) Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the Internet. Forensic Toxicol 29:51–55CrossRef

29.

Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Hamano T (2011) Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29:95–110CrossRef

30.

Nakajima J, Takahashi M, Nonaka R, Seto T, Suzuki J, Yoshida M, Kanai C, Hamano T (2011) Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [³⁵S]GTPγS binding assays. Forensic Toxicol 29:132–141CrossRef

31.

Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13) and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125CrossRef

32.

Nakajima J, Takahashi M, Seto T, Yoshida M, Kanai C, Suzuki J, Hamano T (2012) Identification and quantitation of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone, with other synthetic cannabinoids in unregulated “herbal” products circulated in the Tokyo area. Forensic Toxicol 30:33–44CrossRef

33.

Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int, 2012 Oct 9. pii:S0379-0738(12)00434-3. doi:10.1016/j.forsciint.2012.08.047

34.

Takahashi K, Uchiyama N, Fukiwake T, Hasegawa T, Saijou M, Motoki Y, Kikura-Hanajiri R, Goda Y (2012) Identification and quantitation of a cannabimimetic indole JWH-213 as a designer drug in an herbal product. Forensic Toxicol (in press)

35.

Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR (2003) 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 11:539–549PubMedCrossRef

36.

Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives. WO patent 200128557

37.

Makara JK, Mor M, Fegley D, Szabó SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF, Piomelli D (2005) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139–1141PubMedCrossRef

Title: Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012
Authors: Ruri Kikura-Hanajiri
Nahoko Uchiyama
Maiko Kawamura
Yukihiro Goda
Publication date: 01-01-2013
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 1/2013
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-012-0165-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Real-time near-body drug screening during autopsy I: use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays

Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area

Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity

Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201

A case of drowning lacking typical autopsy findings of carbon monoxide poisoning despite the high CO concentration

Identification and quantitation of JWH-213, a cannabimimetic indole, as a designer drug in a herbal product